Vicore to Present at the DNB Carnegie Nordic Healthcare Conference
STOCKHOLM, SE / ACCESS Newswire / November 20, 2025 /Vicore Pharma Holding AB (publ) (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the DNB Carnegie Nordic Healthcare Conference:
Location: Oslo, Norway
Format: Presentation and 1×1 meetings
Presentation Date and Time: Tuesday, November 25 at 3:35 PM CET
Participant: Hans Jeppsson, CFO
The company 's management team will also be available for meetings at the conference.
For more information, please contact:
Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, megan.richards@vicorepharma.com
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com
About Vicore Pharma
Vicore Pharma Holding AB (publ) is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company 's lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.
The company is publicly listed on the Nasdaq Stockholm exchange (VICO).www.vicorepharma.com
Attachments
Vicore to present at the DNB Carnegie Nordic Healthcare Conference
SOURCE: Vicore Pharma Holding
View the original press release on ACCESS Newswire
© 2025 ACCESS Newswire. All Rights Reserved.
